Ventricular Assist Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Implantable and Percutaneous VAD Markets

Global Ventricular Assist Device Market Report to 2032

The global ventricular assist device market was valued at $1.8 billion in 2025. It is expected to decrease at a compound annual growth rate (CAGR) of -0.4%, reaching $1.77 billion by 2032.

This report covers the global market for ventricular assist devices (VADs), including implantable VADs and percutaneous VADs used to support patients with severe heart failure or acute circulatory support needs.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market performance is supported by technological improvements to implantable VADs and a large potential patient population. However, the invasive nature of VAD implantation, competition from artificial hearts, and recent recall-related pressure in the percutaneous VAD segment are expected to limit stronger growth.

Market Overview

The global ventricular assist device market includes mechanical circulatory support technologies used to assist heart function in patients with advanced heart failure, cardiogenic shock, or other severe cardiac conditions.

The market includes implantable VADs and percutaneous VADs. Implantable devices are typically used for longer-term support in patients awaiting transplant or patients receiving destination therapy. Percutaneous VADs are used for shorter-term support in acute or high-risk procedural settings.

The global VAD market is expected to decline through 2028 before returning to modest growth over the remainder of the forecast period. This near-term contraction is driven largely by reduced utilization and deferred capital spending in the percutaneous VAD segment following high-profile recalls.

In contrast, the implantable VAD segment is expected to remain more resilient. Demand for durable heart failure support remains strong because transplant availability is limited and many patients require long-term mechanical support. As regulatory issues are addressed and clinical confidence stabilizes, both implantable and percutaneous VAD segments are expected to gradually recover.

Market Drivers

Technological Improvements to Implantable VADs

Technological improvements to implantable VADs are a major driver of the market. As VAD technology has matured, manufacturers have made refinements in device design, safety, and performance.

Newer devices are designed to improve patient mobility and reduce reliance on intensive care unit management. These improvements help patients manage life with long-term mechanical circulatory support more effectively.

VADs have also become more compact and easier to implant. These changes can improve patient outcomes, increase quality of life, and support greater confidence among both surgeons and patients. Technological advancements can also increase ASPs, which supports overall market value.

Large Potential Patient Populations

The VAD market is supported by a large potential patient population. Close to one million people in Europe and 600,000 people in the United States are estimated to suffer from end-stage heart failure.

Approximately 20% of these patients may potentially qualify for some type of VAD. This creates a large addressable population for both implantable and percutaneous support technologies.

In 2025, unit sales of implantable VADs remained consistent with a low penetration rate. Increasing penetration within this patient base is expected to support long-term market opportunity, even as near-term market performance is affected by recalls, clinical scrutiny, and capital spending delays.

Limited Transplant Availability

Limited heart transplant availability continues to support demand for VADs. Many patients with advanced heart failure require mechanical support while waiting for a donor heart.

In some cases, VADs are also used as destination therapy for patients who are not expected to receive a transplant. This allows VADs to extend life and support heart function in patients with limited treatment alternatives.

Because donor hearts remain scarce, VADs will continue to play an important role in advanced heart failure care. This underlying clinical need supports the market despite near-term headwinds in certain segments.

Market Limiters

Invasive Method of Replacement

The invasive nature of VAD implantation is a major limiter for the market. Implantable VAD placement usually requires open-heart surgery through a median sternotomy.

VADs also involve blood flowing over a non-biologic surface, which creates a higher risk of clotting. Because of this, patients often require anticoagulation therapy after implantation.

Percutaneous VADs partially address the invasive nature of treatment by offering less invasive short-term support. However, implantable and external VADs still require invasive procedures, which will continue to limit broader adoption and market growth.

Artificial Hearts

Artificial hearts represent a potential long-term limiter for the VAD market. VADs provide life-saving support for patients awaiting donor hearts and can extend life for destination therapy patients, but they do not fully replace heart function.

VADs are pumps that assist the heart and may slow or reverse the progression of heart failure. Artificial hearts, by contrast, are intended to act as a complete substitute for the natural human heart.

Significant advancements in artificial heart technology are expected over the forecast period. If these technologies improve and become more widely adopted, they could cannibalize VAD use, especially in the destination therapy market where patients are not expected to receive a transplant.

Recall-Related Market Pressure

Recent recall activity has created pressure in the percutaneous VAD segment. From 2023 to 2025, Abiomed faced several FDA Class I recalls affecting Impella systems, including a major recall in March 2024 related to the risk of left ventricular wall perforation.

These events have increased clinical scrutiny, affected utilization, and contributed to deferred capital spending. Hospitals and physicians may be more cautious in the near term as updated usage guidelines are adopted.

Although clinical confidence is expected to stabilize over time, recall-related pressure is a major reason the overall VAD market is expected to decline through 2028 before returning to modest growth.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers ventricular assist devices used for advanced heart failure and circulatory support, including implantable VADs and percutaneous VADs.

Markets Covered and Segmentation

Ventricular Assist Device Market

• Device type: Implantable VADs and percutaneous VADs.

Implantable VADs are used for longer-term mechanical circulatory support. These devices are commonly used for bridge-to-transplant patients and destination therapy patients who require durable support due to advanced heart failure.

Percutaneous VADs are used for temporary support in acute settings, high-risk procedures, or cardiogenic shock. These products are inserted through less invasive access routes and are designed for shorter-term circulatory support.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how implantable and percutaneous technologies differ in terms of clinical use, patient selection, capital purchasing, recall pressure, and long-term growth potential.

Competitive Analysis

Abbott was the largest competitor in the global VAD market in 2025. The company offers implantable VADs through its HeartMate 2(TM) and HeartMate 3(TM) products.

HeartMate 3(TM), Abbott's latest-generation implantable VAD, launched in August 2017 and has seen widespread adoption in the United States, particularly after FDA approval for destination therapy use in patients with advanced heart failure. Abbott also markets the CentriMag(R) Acute Circulatory Support System in the external VAD segment, which is FDA-approved to provide up to six hours of short-term circulatory support during cardiac surgery.

Abiomed, now part of Johnson & Johnson MedTech, held the second-leading position in the global VAD market in 2025. The company focuses mainly on percutaneous VADs through its Impella(TM) product line, including Impella 2.5(R), CP(R), 5.0(R), 5.5(R), LD(R), and RP(R).

From 2023 to 2025, Abiomed faced several FDA Class I recalls affecting Impella systems, including the March 2024 recall related to the risk of left ventricular wall perforation. Despite these challenges, the company strengthened its clinical position in March 2025 when the ACC/AHA upgraded the Impella recommendation to Class IIa for STEMI-associated cardiogenic shock.

Berlin Heart ranked as the third-leading competitor in the VAD market in 2025. Its EXCOR Pediatric VAD is an external VAD designed to support pediatric patients with severe ventricular dysfunction while awaiting heart transplantation. The device can function as an LVAD, RVAD, or BiVAD depending on patient need.

Technology and Practice Trends

Implantable VAD Refinement

Implantable VAD technology continues to improve through better design, smaller form factors, and greater patient mobility.

These improvements support patient quality of life and help build confidence in long-term mechanical circulatory support.

Percutaneous VAD Recovery

The percutaneous VAD segment is expected to recover gradually as recall-related issues are addressed and clinical confidence stabilizes.

Updated usage guidance and stronger clinical oversight may help rebuild adoption over time.

Destination Therapy

Destination therapy remains an important use case for VADs. These patients are not expected to receive a heart transplant but may benefit from long-term mechanical support.

This use case supports continued demand for durable implantable VADs.

Bridge to Transplant

VADs remain important for patients awaiting donor hearts. Because transplant availability is limited, many patients require mechanical support while waiting.

This continues to provide a stable clinical role for VADs in advanced heart failure treatment.

Pediatric Mechanical Support

Pediatric VADs serve a small but high-risk patient group with limited alternatives. Berlin Heart's EXCOR Pediatric VAD is an example of a specialized device designed for this population.

This segment is clinically important despite its smaller market size.

Competition from Artificial Hearts

Artificial hearts may become more important over the forecast period as technology improves. These devices could compete most directly with VADs in destination therapy patients.

The level of cannibalization will depend on device performance, regulatory approvals, clinical adoption, and patient selection.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global ventricular assist device market today, and how is it expected to change through 2032?
• How are implantable and percutaneous VAD segments performing differently?
• Why is the market expected to decline through 2028 before returning to modest growth?
• How are recall-related issues affecting percutaneous VAD utilization and capital spending?
• What role do VADs play in bridge-to-transplant and destination therapy patients?
• How does limited heart transplant availability support long-term VAD demand?
• How are technological improvements making implantable VADs more compact and patient-friendly?
• What risks are created by invasive implantation methods and anticoagulation needs?
• How could artificial hearts affect the future of the VAD market?
• Which companies lead the global ventricular assist device market?

The Global Ventricular Assist Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand mechanical circulatory support trends, and support commercial planning in the global VAD market.